Janssen's Psoriatic Arthritis Drug Proves Long-Term Efficacy in Two-Year Trial

Janssen's Psoriatic Arthritis Drug Proves Long-Term Efficacy in Two-Year Trial

Source: 
BioSpace
snippet: 

Long-term data from Janssen’s Phase III DISCOVER-2a trial show that TREMFYA® (guselkumab), a selective IL-23 inhibitor, lead to skin clearance and joint symptom relief for up to two years in patients with active psoriatic arthritis (PsA).